TD Cowen maintains $67 target on Bristol-Myers Squibb By Investing.com

On Thursday, TD Cowen sustained its Hold rating on shares of Bristol-Myers Squibb Co. (NYSE:) with a consistent price target of $67.00. The firm’s commentary highlighted a comparative analysis between Bristol’s Camzyos and a competing drug, aficamten, developed by Cytokinetics (NASDAQ:). The analysis noted that despite some differences in trial designs, aficamten may present a more favorable efficacy and safety profile than Camzyos. A particularly lower percentage of patients on aficamten had left ventricular ejection fraction (LVEF) below 50%, and the drug was associated with fewer serious adverse cardiac events (SAEs).

The report also mentioned that aficamten’s safety and efficacy advantages could lead to a less stringent Risk Evaluation and Mitigation Strategy (REMS) program, potentially making it the preferred option for new patients requiring cardiac myosin inhibition. Despite this, Camzyos is backed by emerging real-world experience that suggests a positive profile, which could influence its position in the market.

Cytokinetics is expected to file regulatory submissions for aficamten in the United States and the European Union in the third and fourth quarters of 2024, respectively. This development could impact the market dynamics for cardiac myosin inhibitors, as healthcare providers may have new treatment options to consider for their patients.

InvestingPro Insights

In light of TD Cowen’s maintained Hold rating on Bristol-Myers Squibb Co. (BMY), recent data from InvestingPro can provide additional context for investors. Bristol-Myers Squibb’s market capitalization stands at $89.46 billion, reflecting the company’s significant presence in the pharmaceutical industry. Despite recent challenges in the market, as indicated by a negative price total return over various time frames, the company pays a substantial dividend yield of 5.39%, which is particularly attractive for income-seeking investors.

InvestingPro Tips suggest that management’s active share buyback program may signal confidence in the company’s value. Furthermore, Bristol-Myers Squibb has a strong free cash flow yield, according to valuation metrics, which could be a positive sign for future financial flexibility and shareholder returns.

Investors may also take note that Bristol-Myers Squibb has maintained its dividend payments for an impressive 54 consecutive years, underscoring its…